Silenseed signs $7.8 million agreement with GIBF to create Chinese subsidiary

Israel-based Silenseed, a clinical-stage biopharmaceutical company, has announced that it has signed a Joint Venture Agreement with Guangzhou Sino-Israel Bio-Industry Investment Fund LLP (GIBF). It is understood that the agreement is for the creation of a jointly-owned Chinese subsidiary, Guangzhou Silenseed-China Ltd., and that GIBF will develop, market, and sell Silenseed’s products.

Read more

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email